Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Arthritis Research & Therapy|March 28, 2014
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsJoerg Wendler, Gerd R Burmester, Helmut Sörensen, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Joachim Listing, Jan Zernicke, et al.
Rheumatology and Therapy|September 14, 2021
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial DataMarkus Rehberg, Clemens Giegerich, Amy Praestgaard, et al.
Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
RMD Open|November 2, 2019
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extensionGerd R Burmester, Vibeke Strand, Andrea Rubbert-Roth, et al.
RMD Open|December 6, 2023
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registryAdrian Ciurea, Andrea Götschi, René Bräm, et al.
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAdrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, et al.
Clinical Rheumatology|March 10, 2025
Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohortAnnik Steimer, Andrea Götschi, Torsten Witte, et al.
RMD Open|October 26, 2022
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RAKristin Schmiedeberg, Irene A Abela, Natalia Barbara Pikor, et al.
Pageof 9